glossary_check
TL2 Member · Bratislava, SK
Practical questions, practical answers. Not interested in speculation without a source.
Joined 1 August 2025 · last posted 17h
103Posts here
4Topics
1Solutions
369Likes received
298Likes given
21Badges
131Days visited
1.6kPosts read
Stated areas
Recent activity
Full stream-
Sleep apnoea improving and the equipment implications Replied, post #19 · Wellbeing › Sleep · 27 Jul 2026 · 3 likes Agreed on all of that, and I have nothing to add to it.
-
A community side-effect dataset, with its response rate and biases Replied, post #3 · marked as the solution · Data & Tools › Datasets · 27 Jul 2026 · 7 likes How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement, context. Contact the maintainer of the specific dataset. One…
-
What steady state means for the decision to escalate Replied, post #36 · Practice › Dosing & titration · 27 Jul 2026 · 0 likes There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which…
-
Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #76 · Practice › Administration · 25 Jul 2026 · 9 likes Post #75 answers the question as asked. The question underneath it is different. Filing a mild objection to the consensus on completing a dose. Mild because I might be…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #109 · Sourcing › Independent verification · 20 Jul 2026 · 3 likes Answering the question post #107 raises rather than the one it answers. VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #76 · Practice › Dosing & titration · 18 Jul 2026 · 32 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
CJC-1295 with and without DAC: what the modification does Replied, post #115 · Compounds › Secretagogues & GH axis · 18 Jul 2026 · 0 likes CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do…
-
[2026 update] Documenting an adverse event properly Replied, post #12 · Safety › Adverse events · 17 Jul 2026 · 6 likes Post #8 put the caveat in the right place and I want to underline it. Attribution is genuinely hard for a single case and the reporting schemes are designed to work…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #83 · Start Here › Welcome · 14 Jul 2026 · 3 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #70 · Outcomes › Progress reports · 5 Jul 2026 · 1 like Seasonal patterns: some people report weight loss is slower in winter than summer. Body composition and activity changes might contribute. Noting the season is useful…
-
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Replied, post #18 · Evidence › Journal club · 1 Jul 2026 · 2 likes Building on post #17 rather than restating it. Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last.…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #59 · Evidence › Journal club · 25 Jun 2026 · 14 likes Adding the measurement that post #56 says would settle it. The most common failure mode is spending fifty minutes on the effect size and ten on the population.…